NasdaqCM - Nasdaq Real Time Price USD

Estrella Immunopharma, Inc. (ESLA)

0.9700

-0.0396

(-3.92%)

At close: June 2 at 4:00:00 PM EDT

1.0200

+0.05

+(5.15%)

After hours: June 2 at 7:07:03 PM EDT

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Name	Title	Pay	Exercised	Year Born
Dr. Cheng Liu Ph.D.	CEO, President & Director	250k	--	1967
Mr. Jiandong Xu	Chief Financial Officer	--	--	1973

5858 Horton Street

Suite 370

EmeryVille, CA 94608

United States

510 318 9098 https://www.estrellabio.com

Sector:: Healthcare
Industry:

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.

Estrella Immunopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events Information Not Available

May 29, 2025 at 12:00 AM UTC